U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794956) titled 'LpD3.5 Intervention Study in Older Adults- LISA-I Trial' on Aug. 24.
Brief Summary: This randomized placebo-controlled clinical study, called the LpD3.5 Intervention Study in Older Adults (LISA), aims to evaluate whether a heat-inactivated postbiotic of human origin (LpD3.5) can serve as a non-pharmacological intervention to reduce gut permeability and inflammation in older adults with mild cognitive impairment (MCI). The study will assess the effects of LpD3.5 supplementation on markers associated with gut health, inflammation, microbiome composition, and cognitive function.
Participants aged 60 years or older with clinically diag...